Shaobo Shi1,2, Tao Liu1,2,3, Dandan Wang1,2, Yan Zhang1,2, Jinjun Liang1,2, Bo Yang1,2, Dan Hu1,2,4. 1. Department of Cardiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan, Hubei 430060, China. 2. Cardiovascular Research Institute, Wuhan University, Wuhan, China. 3. Montreal Heart Institute, University of Montreal, Montreal, QC, Canada. 4. Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA.
Abstract
AIMS: The goal of this study was to assess the effects of N-methyl-d-aspartate (NMDA) receptors activation on heart rate variability (HRV) and susceptibility to atrial fibrillation (AF). METHODS AND RESULTS: Rats were randomized for treatment with saline, NMDA (agonist of NMDA receptors), or NMDA plus MK-801 (antagonist of NMDA receptors) for 2 weeks. Heart rate variability was evaluated by using implantable electrocardiogram telemeters. Atrial fibrillation susceptibility was assessed with programmed stimulation in isolated hearts. Compared with the controls, the NMDA-treated rats displayed a decrease in the standard deviation of normal RR intervals, the standard deviation of the average RR intervals, the mean of the 5-min standard deviations of RR intervals, the root mean square of successive differences, and high frequency (HF); and an increase in low frequency (LF) and LF/HF (all P< 0.01). Additionally, the NMDA-treated rats showed prolonged activation latency and reduced effective refractory period (all P< 0.01). Importantly, AF was induced in all NMDA-treated rats. While atrial fibrosis developed, connexin40 downgraded and metalloproteinase 9 upgraded in the NMDA-treated rats (all P< 0.01). Most of the above alterations were mitigated by co-administering with MK-801. CONCLUSION: These results indicate that NMDA receptors activation reduces HRV and enhances AF inducibility, with cardiac autonomic imbalance, atrial fibrosis, and degradation of gap junction protein identified as potential mechanistic contributors. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The goal of this study was to assess the effects of N-methyl-d-aspartate (NMDA) receptors activation on heart rate variability (HRV) and susceptibility to atrial fibrillation (AF). METHODS AND RESULTS: Rats were randomized for treatment with saline, NMDA (agonist of NMDA receptors), or NMDA plus MK-801 (antagonist of NMDA receptors) for 2 weeks. Heart rate variability was evaluated by using implantable electrocardiogram telemeters. Atrial fibrillation susceptibility was assessed with programmed stimulation in isolated hearts. Compared with the controls, the NMDA-treated rats displayed a decrease in the standard deviation of normal RR intervals, the standard deviation of the average RR intervals, the mean of the 5-min standard deviations of RR intervals, the root mean square of successive differences, and high frequency (HF); and an increase in low frequency (LF) and LF/HF (all P< 0.01). Additionally, the NMDA-treated rats showed prolonged activation latency and reduced effective refractory period (all P< 0.01). Importantly, AF was induced in all NMDA-treated rats. While atrial fibrosis developed, connexin40 downgraded and metalloproteinase 9 upgraded in the NMDA-treated rats (all P< 0.01). Most of the above alterations were mitigated by co-administering with MK-801. CONCLUSION: These results indicate that NMDA receptors activation reduces HRV and enhances AF inducibility, with cardiac autonomic imbalance, atrial fibrosis, and degradation of gap junction protein identified as potential mechanistic contributors. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Alison M Thomas; Claudia P Cabrera; Malcolm Finlay; Kulvinder Lall; Muriel Nobles; Richard J Schilling; Kristie Wood; Charles A Mein; Michael R Barnes; Patricia B Munroe; Andrew Tinker Journal: Physiol Genomics Date: 2019-06-07 Impact factor: 3.107
Authors: Bożena Bądzyńska; Izabela Zakrocka; Waldemar A Turski; Krzysztof H Olszyński; Janusz Sadowski; Elżbieta Kompanowska-Jezierska Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-12-06 Impact factor: 3.000
Authors: Xin Liu; Chuan Qu; Shaobo Shi; Tianxin Ye; Linglin Wang; Steven Liu; Cui Zhang; Jinjun Liang; Dan Hu; Bo Yang Journal: Front Physiol Date: 2019-11-14 Impact factor: 4.755
Authors: Jesse L Ashton; Rebecca A B Burton; Gil Bub; Bruce H Smaill; Johanna M Montgomery Journal: Front Physiol Date: 2018-03-20 Impact factor: 4.566